Expansion of SCG/GCG-Based CAD Sceering: Inclusion of Healthy Controls and CCTA Patients

NACompletedINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

December 26, 2023

Study Completion Date

February 1, 2025

Conditions
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Interventions
DEVICE

Seismocardiography (SCG) and Gyrocardiography (GCG) Screening

"This intervention involves the use of SCG/GCG diagnostic testing, a radiation-free, non-invasive technique for assessing cardiac function. SCG/GCG utilizes high-precision accelerometers and gyroscopes to record and analyze cardiac-induced microvibrations on the chest.~Participants will undergo SCG/GCG testing before their scheduled coronary artery calcium computed tomography (CAC-CT) or coronary computed tomography angiography (CCTA). The study aims to evaluate the diagnostic performance of SCG/GCG in identifying CAD, particularly in hypertensive patients and those with mild CAD.~Data collected from SCG/GCG will be compared with CAC-CT and CCTA findings to determine its predictive value for CAD severity and coronary artery stenosis."

Trial Locations (1)

Unknown

Republic Specialized Scientific-Practical Medical Center of Cardiology (RSPCMCC), Tashkent

All Listed Sponsors
lead

Heart Force Medical Inc.

INDUSTRY

NCT06880133 - Expansion of SCG/GCG-Based CAD Sceering: Inclusion of Healthy Controls and CCTA Patients | Biotech Hunter | Biotech Hunter